To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Functional precision oncology using ex vivo 3D cell culture technology

In high grade glioma, Kiyatec 3D Predict™ accurately predicted therapeutic response rates in > 85% cases, providing physicians with patient-specific therapeutic response insights to inform their treatment planning for each patient.


Our Science & Technology Provide Oncologists with Insights to Improve Clinical Outcomes

Our ex vivo 3D cell culture platforms enable us to utilize a patient's live cancer cells from surgical or biopsy tissue to create a patient-specific,
in vivo-like tumor and immune microenvironment, outside the body, to accurately model and assess response (ex vivo efficacy) to investigational and FDA-cleared cancer therapies.

Our unique ex vivo 3D cell culture approach maximizes patient relevance in the laboratory assessment of drug-on-tumor cell interaction prior to therapy administration, providing clinicians with patient-specific therapeutic response prediction in 7-10 business days, prior to initiation of therapy.

Kiyatec offers clinical testing for high-grade glioma and is developing tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified lab. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.

Kiyatec is disrupting cancer care by providing oncologists with a functional precision assay that accurately predicts patient–specific therapeutic response and non–response before treatment begins.

Kiyatec is a leader in functional precision oncology. Kiyatec utilizes proprietary platforms across multiple solid tumor types, based on robust science that scores >95th percentile in peer reviewed journals.
Have any questions or want to learn more?


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram